Andere Kunden interessierten sich auch für
![Targeting Oncogenic Driver Mutations in Lung Cancer]( "Targeting Oncogenic Driver Mutations in Lung Cancer")
Targeting Oncogenic Driver Mutations in Lung Cancer23,99 €![Egfr-Directed Therapy in Lung Cancer]( "Egfr-Directed Therapy in Lung Cancer")
Egfr-Directed Therapy in Lung Cancer24,99 €![Diagnosis and Treatment of Rare Gynecologic Cancers]( "Diagnosis and Treatment of Rare Gynecologic Cancers")
Diagnosis and Treatment of Rare Gynecologic Cancers121,99 €![Personalized Drug Screening for Functional Tumor Profiling]( "Personalized Drug Screening for Functional Tumor Profiling")
Personalized Drug Screening for Functional Tumor Profiling25,99 €![Overcoming Cancers Resistant to Her-2 Antibodies]( "Overcoming Cancers Resistant to Her-2 Antibodies")
Overcoming Cancers Resistant to Her-2 Antibodies143,99 €![Cancer Targeting Therapies]( "Cancer Targeting Therapies")
Cancer Targeting Therapies103,99 €![Targeting Cell Survival Pathways to Enhance Response to Chemotherapy]( "Targeting Cell Survival Pathways to Enhance Response to Chemotherapy")
Targeting Cell Survival Pathways to Enhance Response to Chemotherapy184,99 €
The KRAS oncogene is believed to be the most common single nucleotide variant oncogene in human cancer. Historically, efforts to target KRAS and the other RAS GTPases have struggled. More recently, efforts have focused on identifying and exploiting features unique to specific oncogenic mutations.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.